GleamWall
中文EN

XNCR Xencor Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1326732 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY19.8%
TTM net income YoY15.1%
TTM EPS YoY9.8%
Revenue 3-yr CAGR11.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-72.7%
Net margin-58.8%
FCF margin-88.0%
EBITDA margin-67.9%

Returns

ROE-19.9%
ROA-14.4%
ROIC (approx.)-17.4%
Asset turnover0.24x

Leverage & solvency

Liabilities / assets27.3%
Debt / equity0.17x
Current ratio6.54x
Interest coverage-6.19x

Cash quality & payout

Operating cash flow / net income1.46x
Accruals ratio6.6%
Payout ratio—
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$125.58M$110.49M
R&D expense$239.43M$227.69M
SG&A expense$63.64M$61.22M
Operating income-$177.50M-$178.41M
Interest expense$31.93M$36.64M
Pretax income-$89.63M-$234.92M
Income tax$2.50M$1.62M
Net income-$91.92M-$232.62M
EBITDA-$166.99M-$166.30M
EPS (basic)-1.24-3.58
EPS (diluted)-1.24-3.58
Weighted avg. shares (diluted)74.24M65.04M
Banking
Net interest income—$31.93M
Balance sheet
Cash & equivalents$54.07M$41.26M
Receivables$29.30M$60.85M
Current assets$599.82M$577.60M
PP&E, net$53.31M$59.80M
Intangibles$8.38M$18.48M
Total assets$875.50M$951.95M
Current liabilities$95.91M$87.43M
Short-term debt$43.27M$48.45M
Long-term debt$76.48M$115.16M
Total debt$119.75M$163.61M
Total liabilities$239.91M$277.92M
Shareholders' equity$635.59M$677.61M
Net debt$65.68M$122.34M
Shares outstanding71.87M70.26M
Cash flow statement
Operating cash flow-$135.12M-$202.19M
Capital expenditure$3.15M$6.10M
Free cash flow-$138.27M-$208.28M
Investing cash flow$139.99M-$7.87M
Financing cash flow$8.23M$197.15M
Depreciation & amortization$10.51M$12.11M
Stock-based compensation$43.23M$53.28M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.